Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 12/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8112178 | 0.84 | LTA4H (0.57) | LTA4HNPC1RAB9APOLBHCRTR2 | |
| SCHEMBL3494092 | 0.82 | LTA4H (0.68) | LTA4HPTGS1PTGS2ACHE | |
| SCHEMBL2108222 | 0.81 | LTA4H (1.00) | LTA4H | |
| SCHEMBL5685382 | 0.81 | LTA4H (0.72) | LTA4HPTGS1PTGS2ACHE | |
| Hydrochloric Acid SCHEMBL8773798 | 0.81 | LTA4H (0.98) | LTA4H | |
| SCHEMBL17833499 | 0.77 | LTA4H (0.83) | LTA4H | |
| SCHEMBL2108955 | 0.76 | LTA4H (1.00) | LTA4H | |
| SCHEMBL8641130 | 0.74 | LTA4H (0.56) | LTA4HNPC1RAB9APOLBPTGS1 | |
| SCHEMBL8638399 | 0.73 | LTA4H (0.55) | LTA4HNPC1RAB9APOLBPTGS1 | |
| SCHEMBL5684514 | 0.72 | LTA4H (0.62) | LTA4HNPC1RAB9APOLBPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0843549-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2006-04-12 | — | — | EP | claimed |
| US-20050043355-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | claimed |
| US-20030004191-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | PHARMACIA CORPORATION | 2003-01-02 | — | — | US | claimed |
| EP-0880363-B1 | COMBINATIONS, HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2002-09-11 | — | — | EP | claimed |
| US-6407140-B1 | AUTOIMMUNE DISEASES, GRAFT VERSUS HOST DISEASE AND ORGAN TRANSPLANT SURGERY; PYRAZOLE DERIVATIVE MIXTURE | G.D. SEARLE & CO. | 2002-06-18 | — | — | US | claimed |
| EP-0880363-A1 | COMBINATIONS, HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4? HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-12-02 | — | — | EP | claimed |
| EP-0843549-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4? HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-05-27 | — | — | EP | claimed |
| WO-1997029774-A1 | COMBINATIONS, HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1996041625-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043355-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | LTA4H, LTB4R2, LTB4R | LTA4H 1/4885NPC1 3819/4885RAB9A 4630/4885 |
| US-20030004191-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | LTA4H, LTB4R2, LTC4S | LTA4H 1/4885NPC1 3819/4885RAB9A 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.